Doxycycline Hyclate

CAS 24390-14-5 9 current records 6 historicalSmall Molecule

Who holds supplier records for Doxycycline Hyclate? 9 organisations hold a current record for Doxycycline Hyclate: an active US FDA Type II Drug Master File or a CEP. A further 6 organisations have only historical (inactive) DMF filings. 6 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: China (4), India (3) and Macau (1); not recorded for 1.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Doxycycline Hyclate: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/doxycycline-hyclate

Reading the evidence

  • 9 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 3 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Doxycycline Hyclate expires 23 Dec 2034. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (9)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Doxycycline Hyclate. Country is the organisation's recorded country, not necessarily the manufacturing site.

China4India3Macau1Country not recorded for 1
Need Doxycycline Hyclate sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (6)

Certificates of Suitability on the EDQM register for Doxycycline Hyclate, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 11 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
HOVIONE PHARMASCIENCE LIMITED TaipaMO
CEP 1996-066 - Rev 08
Doxycycline hyclate
Apr 2026—
SHANDONG GUOBANG PHARMACEUTICAL CO., LTD. WeifangCN
CEP 2022-336 - Rev 01
Doxycycline hyclate
Mar 2026—
YANCHENG SUHAI PHARMACEUTICAL CO., LTD. Dafeng District, Yancheng CityCN
CEP 1999-100 - Rev 06
Doxycycline hyclate
Aug 2025—
YANGZHOU LIBERTY PHARMACEUTICAL CO., LTD. YangzhouCN
CEP 2000-165 - Rev 08
Doxycycline hyclate
Feb 2025—
RAKS PHARMA PVT. LTD. VisakhapatnamIN
R1-CEP 2014-175 - Rev 00
Doxycycline hyclate
Feb 2022—
KAIFENG PHARMACEUTICAL (GROUP) CO., LTD. KaifengCN
R1-CEP 2001-038 - Rev 02
Doxycycline hyclate
Mar 2015—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (6)

Organisations whose Type II DMFs for Doxycycline Hyclate are no longer active. These show a past filing, not current supply.

Show all 6 historical records

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (83 listed products contain Doxycycline Hyclate). The latest listed patent expires 23 Dec 2034. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Doxycycline Hyclate is a tetracycline-class antibiotic used to treat a variety of bacterial infections. It is particularly effective against infections like pneumonia, acne, and certain types of urinary tract infections.

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Tetracycline-class Drug
Chemical structure
Tetracyclines

Therapeutic areas

Infectious DiseaseDermatologyRespiratory Tract Infections

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Doxycycline Hyclate?

9 organisations hold an active US FDA Type II Drug Master File or a CEP for Doxycycline Hyclate: YANGZHOU LIBERTY PHARMACEUTICAL CO LTD (China), CHANGZHOU PHARMACEUTICAL FACTORY (China), HOVIONE PHARMASCIENCE LTD (Macau), RAKS PHARMA PVT LTD (India), Shandong Guobang Pharmaceutical Co., Ltd. (China), YANCHENG SUHAI PHARMACEUTICAL CO LTD (China), GLAND PHARMA LTD (India) and MAITHRI DRUGS PRIVATE LTD (India), and 1 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Doxycycline Hyclate Drug Master Files are active?

YANGZHOU LIBERTY PHARMACEUTICAL CO LTD (DMF 13174, 41804), CHANGZHOU PHARMACEUTICAL FACTORY (DMF 13771, 40709), HOVIONE PHARMASCIENCE LTD (DMF 13714), RAKS PHARMA PVT LTD (DMF 25955), Shandong Guobang Pharmaceutical Co., Ltd. (DMF 42567), YANCHENG SUHAI PHARMACEUTICAL CO LTD (DMF 16191, 36491), GLAND PHARMA LTD (DMF 33093) and MAITHRI DRUGS PRIVATE LTD (DMF 41689). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Doxycycline Hyclate records mean?

6 organisations have only inactive Type II DMFs for Doxycycline Hyclate. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Doxycycline Hyclate have a European Certificate of Suitability?

Yes. 6 organisations hold a valid CEP for Doxycycline Hyclate on the EDQM register, including HOVIONE PHARMASCIENCE LIMITED Taipa (MO), SHANDONG GUOBANG PHARMACEUTICAL CO., LTD. Weifang (CN), YANCHENG SUHAI PHARMACEUTICAL CO., LTD. Dafeng District, Yancheng City (CN), YANGZHOU LIBERTY PHARMACEUTICAL CO., LTD. Yangzhou (CN), RAKS PHARMA PVT. LTD. Visakhapatnam (IN) and KAIFENG PHARMACEUTICAL (GROUP) CO., LTD. Kaifeng (CN). A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Doxycycline Hyclate?

Yes. The latest patent listed for an approved US product containing Doxycycline Hyclate expires 23 Dec 2034, across 83 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Doxycycline Hyclate supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Doxycycline Hyclate?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.